Canadian guideline for Parkinson disease

Abstract

P arkinson disease is chronic and progressive in nature, decreasing the quality of life for both patients with the disease and their caregivers and placing an onerous economic burden on society. 1 The first Canadian guideline on Parkinson disease was published in 2012. 2 Since that guideline, there have been substantial advances in the literature on the disease, particularly with respect to diagnostic criteria and treatment options. Parkinson Canada undertook to update the existing guideline to reflect these advances, as well as to add information on palliative care. With the aim of enhancing care for all Canadians with Parkinson disease, this guideline is based on the best published evidence, involves expert consensus when there is a lack of evidence, offers practical clinical advice, takes patient choice and informed decision-making into account and is relevant to the Canadian health care system. The guideline has been divided into 5 main sections to improve the ease of use: communication, diagnosis and progression, treatment, nonmotor features and palliative care. The full guideline is available in Appendix 1, at www.cmaj.ca/lookup/ suppl/

Functional Connectivity in Parkinson's Disease Patients with Mild Cognitive Impairment

“…Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder, decreasing the quality of life and placing serious social and economic burdens [1]. In China, the prevalence of PD is 1700 per 100,000 in individuals older than 65 years, which is similar to the rate reported in developed countries [2,3].…”

Covid-19 Pandemisinde Neuman Sistemler Modeli Işığında Parkinsonlu Bireye Uygulanan Hemşirelik Bakımı: Olgu Sunumu

“…Dördüncü görüşme 20 Mayıs 2020 tarihinde hastanın ailesiyle Parkinson hastalığı ve hasta ile iletişim konularına yönelik olarak yapılmış, hasta görüşmeye dahil edilmemiştir. Uluslararası rehberler tarafından Parkinson hastası bireye verilecek eğitimlerin aynı zamanda yazılı olarak da verilmesi önerilmektedir (Grimes et al, 2019;NICE Guideline, 2017). Bu öneri doğrultunda hastaya verilen konstipasyon (önleme), beslenme (konstipasyonu önleme, yeterli ve dengeli beslenme), fiziksel aktivite (yararları, günlük egzersiz programı) ve düşme riski (düşmenin önemi, neden olan durumlar ve önleme) eğitim içerikleri e-posta ve telefon aracılığıyla hasta ve ailesiyle paylaşılmıştır.…”

Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease

“…The deposition of Aβ and α-syn activates microglia in the brain and triggers neuroinflammation, which leads to memory and cognitive impairment in AD patients and motor and non-motor symptoms in PD patients (Rogers et al 2007). With the advent of an aging population, more and more people are suffering from AD and PD, but only a few drugs are available for the two diseases mentioned above, and they can only relieve symptoms but fail to halt the progression of the diseases (Du et al 2018;Grimes et al 2019). Therefore, developing drugs targeting common contributors of AD and PD may be a wise strategy.…”